product name Nimodipine
Description: Nimodipine (also known as BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure. Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine is mainly used in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed).
References: J Neurophysiol. 1992 Dec;68(6):2100-9; Hear Res. 1990 Jul;46(3):277-87.
418.44
Formula
C21H26N2O7
CAS No.
66085-59-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 84 mg/mL (200.7 mM)
Water: < 1 mg/mL
Ethanol: 84 mg/mL (200.7 mM)
Solubility (In vivo)
Synonyms
BAY E 9736
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19396379
| In Vitro |
In vitro activity: Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons. Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaines effects, but only partially blocks sensitization to cocaine. Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. |
| Animal model | |
| Formulation & Dosage | |
| References | J Neurophysiol. 1992 Dec;68(6):2100-9; Hear Res. 1990 Jul;46(3):277-87. |
Related Posts
product name Nimodipine
Description: Nimodipine (also known as BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure. Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine is mainly used in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed).
References: J Neurophysiol. 1992 Dec;68(6):2100-9; Hear Res. 1990 Jul;46(3):277-87.
418.44
Formula
C21H26N2O7
CAS No.
66085-59-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 84 mg/mL (200.7 mM)
Water: < 1 mg/mL
Ethanol: 84 mg/mL (200.7 mM)
Solubility (In vivo)
Synonyms
BAY E 9736
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19396379
| In Vitro |
In vitro activity: Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons. Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaines effects, but only partially blocks sensitization to cocaine. Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. |
| Animal model | |
| Formulation & Dosage | |
| References | J Neurophysiol. 1992 Dec;68(6):2100-9; Hear Res. 1990 Jul;46(3):277-87. |